Full Press Release Details
Medical 's LIBERTY Endovascular Robotic System Continues to Expand Market Visibility; Being Featured
at an Industry Leading Innovation Conference
Global Robotic Leaders Convene to Discuss & Highlight Surgical Advancements of
the Next Decade with a Special Focus on the Endovascular Space
Mass., February 19, 2026 -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular
Robotic System, announced that Harel Gadot, CEO, President and Chairman, will be a featured panelist at The Surgical Disruptive Technology
Summit, which is part of SAGES NBT Innovation Weekend, taking place February 19-21 in Houston, TX. SAGES's mission is to innovate,
educate and collaborate to improve patient care, and the SAGES NBT Innovation Weekend serves as an open forum for dialogue between industry
and providers on innovations in surgical technology and surgical practice.
thought leaders, including robotic pioneers, will discuss advancing technologies with a focus on minimally invasive and less invasive
interventions. A dedicated panel, titled Endovascular Therapeutics: AI and Robotics, will provide Mr. Gadot with a platform to
highlight the unique features of the LIBERTY System, allowing the Company to establish a new category of surgical robotics. The Company
believes that the growing confidence in AI and robotic innovations in endovascular procedures can support the accelerated adoption of
LIBERTY. These innovations include remote interventions, precision navigation, and catheter-based robotics designed to enhance access,
safety, and clinical outcomes across vascular care.
believe that the continued emergence of the LIBERTY System, together with the expanding range of procedures performed to date, is redefining
how endovascular care is delivered today and how it will be delivered years ahead," commented Mr. Gadot. "The dedicated session
around the Endovascular space serves as another proof of the opportunities it holds. LIBERTY's distinct advantages, including its
single-use, compact robotic design, are intended to remove many of the barriers that have historically limited the broader adoption of
surgical robotics. We believe this positions LIBERTY as a new class of surgical robotics, expanding access to advanced robotics and enabling
high quality care for a broader range of health systems and patients."
is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for
precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release
of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in
April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.
Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through
advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the world's first FDA cleared
single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property
portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
more at www.microbotmedical.com and connect on LinkedIn and X.
to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development,
commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including,
but not limited to statements that contain words such as "contemplates," "continues," "could," "forecasts,"
"intends," "may," "might," "possible," "potential," "predicts,"
"projects," "should," "would," "will," "believes," "plans," "anticipates,"
"expects," "estimates" and similar expressions) should also be considered to be forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,
including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY Endovascular
Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory
pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes
in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from
new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual
property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors"
in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's
web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements,
except as required by law.